The Use of Autologous Mesenchymal Stem Cells for Cell Therapy of Patients with Amyotrophic Lateral Sclerosis in Belarus

Rushkevich, Yuliya; Kosmacheva, S. M.; Zabrodets, G. V.; Ignatenko, Stanislav; Гончарова, Н. В.; Séverin, Isabelle; Sa, Likhachev; Потапнев, М. П.

doi:10.1007/s10517-015-3017-3

Cited by 37 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, the combined administration of normal MSCs and MSCs committed to neuronal differentiation was revealed to be able to slow down the disease progression in 10 patients in comparison with the control group, receiving a standard symptomatic therapy, after a 12-month follow-up [87].…”

Section: Msc Administration In Als Patientsmentioning

confidence: 99%

Mesenchymal Stem Cells: A Potential Therapeutic Approach for Amyotrophic Lateral Sclerosis?

Bramantı

Mazzon

2019

Stem Cells International

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the degeneration of both upper and lower motor neurons. Patients show both motor and extra-motor symptoms. A cure is not available at this time, and the disease leads to death within 3–5 years, mainly due to respiratory failure. Stem cell therapy is arising as a new promising approach for the treatment of neurodegenerative disorders. In particular, mesenchymal stem cells (MSCs) seem the most suitable type of stem cells, thanks to their demonstrated beneficial effects in different experimental models, to the easy availability, and to the lack of ethical problems. In this review, we focused on the studies involving ALS rodent models and clinical trials in order to understand the potential beneficial effects of MSC transplantation. In different ALS rodent models, the administration of MSCs induced a delay in disease progression and at least a partial recovery of the motor function. In addition, clinical trials evidenced the feasibility and safety of MSC transplantation in ALS patients, given that no major adverse events were recorded. However, only partial improvements were shown. For this reason, more studies and trials are needed to clarify the real effectiveness of MSC-based therapy in ALS.

show abstract

Section: Msc Administration In Als Patientsmentioning

confidence: 99%

Mesenchymal Stem Cells: A Potential Therapeutic Approach for Amyotrophic Lateral Sclerosis?

Bramantı

Mazzon

2019

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…In all trials, autologous cell therapy proved to be a safe procedure. The recipient tissues did not exhibit any structural changes, tumor formation or toxicity related to transplantation, while it was shown to be effective in counteracting disease progression, improving the quality of patient’s life[137-139].…”

Section: Msc Transplantation For Amyotrophic Lateral Sclerosismentioning

confidence: 99%

Orchestrating stem cell fate: Novel tools for regenerative medicine

Cruciani¹,

Santaniello²,

Montella³

et al. 2019

WJSC

View full text Add to dashboard Cite

Mesenchymal stem cells are undifferentiated cells able to acquire different phenotypes under specific stimuli. In vitro manipulation of these cells is focused on understanding stem cell behavior, proliferation and pluripotency. Latest advances in the field of stem cells concern epigenetics and its role in maintaining self-renewal and differentiation capabilities. Chemical and physical stimuli can modulate cell commitment, acting on gene expression of Oct-4, Sox-2 and Nanog, the main stemness markers, and tissue-lineage specific genes. This activation or repression is related to the activity of chromatin-remodeling factors and epigenetic regulators, new targets of many cell therapies. The aim of this review is to afford a view of the current state of in vitro and in vivo stem cell applications, highlighting the strategies used to influence stem cell commitment for current and future cell therapies. Identifying the molecular mechanisms controlling stem cell fate could open up novel strategies for tissue repairing processes and other clinical applications.

show abstract

“…[ 141,142 ] Postmortem evaluation of ALS patients treated with MSCs showed that a more significant number of motor neurons were preserved at the height of the spinal cord area where the cells were administered, compared to other spinal sites. [ 140,143,144 ] Observed clinical improvement in the post‐transplantation ALS recipients might also be related to MSCs' immunomodulatory effect. Recently, Phase II randomized controlled clinical trial was conducted in 48 ALS patients treated with autologous genetically modified MSCs overexpressed neurotrophic factor (NTF) delivered via intramuscular and IT injection.…”

Section: Experimental Attempts To Use Mesenchymal Stem Cells In the Tmentioning

confidence: 99%

Mesenchymal Stem Cells for Neurological Disorders

et al. 2021

View full text Add to dashboard Cite

Neurological disorders are becoming a growing burden as society ages, and there is a compelling need to address this spiraling problem. Stem cell‐based regenerative medicine is becoming an increasingly attractive approach to designing therapies for such disorders. The unique characteristics of mesenchymal stem cells (MSCs) make them among the most sought after cell sources. Researchers have extensively studied the modulatory properties of MSCs and their engineering, labeling, and delivery methods to the brain. The first part of this review provides an overview of studies on the application of MSCs to various neurological diseases, including stroke, traumatic brain injury, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, Parkinson's disease, and other less frequently studied clinical entities. In the second part, stem cell delivery to the brain is focused. This fundamental but still understudied problem needs to be overcome to apply stem cells to brain diseases successfully. Here the value of cell engineering is also emphasized to facilitate MSC diapedesis, migration, and homing to brain areas affected by the disease to implement precision medicine paradigms into stem cell‐based therapies.

show abstract

The Use of Autologous Mesenchymal Stem Cells for Cell Therapy of Patients with Amyotrophic Lateral Sclerosis in Belarus

Cited by 37 publications

References 15 publications

Mesenchymal Stem Cells: A Potential Therapeutic Approach for Amyotrophic Lateral Sclerosis?

Mesenchymal Stem Cells: A Potential Therapeutic Approach for Amyotrophic Lateral Sclerosis?

Orchestrating stem cell fate: Novel tools for regenerative medicine

Mesenchymal Stem Cells for Neurological Disorders

Contact Info

Product

Resources

About